IRIS
BIANCHINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.868
AS - Asia 2.808
NA - Nord America 2.256
SA - Sud America 431
Continente sconosciuto - Info sul continente non disponibili 388
AF - Africa 43
AN - Antartide 1
OC - Oceania 1
Totale 8.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.088
RU - Federazione Russa 1.740
SG - Singapore 1.035
CN - Cina 940
IT - Italia 563
BR - Brasile 350
HK - Hong Kong 329
VN - Vietnam 217
DE - Germania 122
FR - Francia 121
BD - Bangladesh 117
CA - Canada 88
GB - Regno Unito 75
NL - Olanda 72
FI - Finlandia 59
IN - India 47
MX - Messico 36
AR - Argentina 30
PL - Polonia 28
AT - Austria 22
JP - Giappone 21
ZA - Sudafrica 18
CO - Colombia 17
SE - Svezia 17
EC - Ecuador 14
ES - Italia 14
ID - Indonesia 14
PK - Pakistan 14
IQ - Iraq 13
TR - Turchia 12
CR - Costa Rica 11
UA - Ucraina 8
GT - Guatemala 7
JM - Giamaica 7
MY - Malesia 7
NP - Nepal 7
PY - Paraguay 6
TN - Tunisia 6
UZ - Uzbekistan 6
VE - Venezuela 6
LT - Lituania 5
TT - Trinidad e Tobago 5
KE - Kenya 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
HU - Ungheria 3
IE - Irlanda 3
JO - Giordania 3
KR - Corea 3
NI - Nicaragua 3
RO - Romania 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
GE - Georgia 2
HN - Honduras 2
KG - Kirghizistan 2
MD - Moldavia 2
OM - Oman 2
PH - Filippine 2
PR - Porto Rico 2
SV - El Salvador 2
TH - Thailandia 2
TW - Taiwan 2
UG - Uganda 2
UY - Uruguay 2
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
GY - Guiana 1
HR - Croazia 1
HT - Haiti 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
MR - Mauritania 1
MT - Malta 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 8.409
Salva come PNG Salva come JPEG
Città #
Singapore 546
Moscow 379
Hong Kong 323
San Jose 282
Ashburn 260
Council Bluffs 201
Dallas 184
Shanghai 151
Beijing 121
Hefei 106
Milan 99
New York 91
Lauterbourg 88
Ho Chi Minh City 83
Santa Clara 72
Los Angeles 61
Hanoi 55
Rome 55
Boardman 48
Nuremberg 39
São Paulo 39
Orem 36
Chicago 29
Montreal 29
Lappeenranta 25
Warsaw 25
Mexico City 24
Guangzhou 23
Helsinki 23
Phoenix 21
Brescia 20
Brooklyn 18
Atlanta 16
Florence 16
London 16
Munich 16
Shenzhen 15
Tokyo 15
Cesano Boscone 14
Poplar 14
Toronto 14
Manchester 13
Buffalo 12
Denver 12
Falkenstein 12
Houston 12
Johannesburg 12
Chennai 11
Rio de Janeiro 11
Bari 10
Boston 10
Curitiba 10
Genoa 10
Calgary 9
Naples 9
San Francisco 9
Stockholm 9
Amsterdam 8
Assago 8
Bologna 8
Brasília 8
Campinas 8
Frankfurt am Main 8
Lahore 8
Las Vegas 8
San José 8
Turin 8
Venice 8
Vienna 8
Washington 8
Belo Horizonte 7
Charlotte 7
Dhaka 7
Hangzhou 7
New Delhi 7
Philadelphia 7
Turku 7
Wolfhagen 7
Baghdad 6
Guatemala City 6
Jiaxing 6
Miami 6
Paris 6
Seattle 6
Belém 5
City of London 5
Comun Nuovo 5
Dublin 5
Hải Dương 5
Jacksonville 5
Lawrence 5
Ottawa 5
Porto Alegre 5
Princeton 5
Quito 5
Reston 5
Tashkent 5
Verona 5
Xuzhou 5
Asunción 4
Totale 4.138
Salva come PNG Salva come JPEG
Nome #
Spatial predictors of immunotherapy response in triple-negative breast cancer 176
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 170
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 152
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial 134
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial 132
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 128
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 119
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 119
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 117
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 114
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 111
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 110
PARP Inhibitors for Breast Cancer Treatment: A Review 107
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 106
[18F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial 103
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer 102
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 100
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 98
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 96
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 95
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 95
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 95
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 93
Immunotherapy for early triple negative breast cancer: research agenda for the next decade 93
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 93
Pet/mri for staging the axilla in breast cancer: Current evidence and the rationale for snb vs. pet/mri trials 92
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 89
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 88
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 88
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 88
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 86
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 86
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 84
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 84
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 83
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 80
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 79
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 79
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 77
An unmet need: tailoring extended adjuvant endocrine therapy. 77
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 74
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 74
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 74
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer 73
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 72
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers 72
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 71
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 71
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer 70
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 70
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 69
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 67
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel 66
Somatostatin response to a mixed meal in normals and in type I diabetics 66
Prognostic significance of a signature based on senescence-related genes in colorectal cancer 66
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial 66
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? 65
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 64
Immunological differences between primary and metastatic breast cancer 64
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY 63
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 63
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 62
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 61
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer 61
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab 60
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer 59
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 59
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 58
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 56
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies 55
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer 55
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. 54
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease 54
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. 54
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 54
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 54
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 53
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 53
Is trastuzumab as a single agent obsolete in early breast cancer? No 52
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. 52
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients 51
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. 50
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies 50
Dissecting time- from tumor-related gene expression variability in bilateral breast cancer 50
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. 49
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 47
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 47
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care 47
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 46
Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? 46
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies 46
Molecular heterogeneity of estrogen receptor-positive breast cancer explains variable and contradictory results of randomized adjuvant chemotherapy trials in breast cancer 46
The immune system and response to HER2-targeted treatment in breast cancer. 46
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES 45
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 45
Association between red and processed meat consumption and colorectal cancer risk: a comprehensive meta-analysis of prospective studies 44
Treatment options in hormone-refractory metastatic prostate carcinoma. 44
Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer 44
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 44
Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief 43
Totale 7.554
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.238
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.238
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 2 1 1 0 0
2022/202322 11 4 1 0 0 2 0 1 0 0 0 3
2023/2024204 0 0 3 3 1 42 12 8 1 3 60 71
2024/20251.778 239 82 15 96 164 150 287 214 232 96 91 112
2025/20266.041 352 387 271 650 456 206 588 446 1.772 395 223 295
2026/2027745 288 457 0 0 0 0 0 0 0 0 0 0
Totale 8.796